Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Rabin Medical Center40 enrolled

Overview

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Alopecia

Interventions

AS101DRUG

Eligibility

Sex: FEMALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women in menopause, over 50 years of age. * Clinically diagnosed for AGA, according to Ludwig scale I-II. Exclusion Criteria: * Women treated with chronic medications. * Use of Minoxidil within 3 months prior to entering study. * Women who have underwent hair transplantation. * Use of drugs with androgenic or anti-androgenic effects. * Any other type of hair loss.

Locations (1)

Unnamed facility

Tel Aviv, Israel

Outcomes

Primary Outcomes

hair density

Secondary Outcomes

Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,

Self-administered satisfaction questionnaire

Central Contacts

Danny Ben Amitai, MD

CONTACT

972-3-9253770

Raziel Lurie, MD

CONTACT

rlurie@bezeqint.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.